These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 397163)

  • 21. Tumor immunity and immunotherapy.
    Boura P; Kountouras J; Lygidakis NJ
    Hepatogastroenterology; 2001; 48(40):1040-4. PubMed ID: 11490795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cancer immunotherapy. A future therapeutical choice?].
    Bertolaccini L; Olivero G
    Minerva Chir; 2001 Apr; 56(2):183-91. PubMed ID: 11353352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
    Lee Y; Bigner DD
    Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunology and cancer].
    Brunner KT
    Schweiz Med Wochenschr; 1973 Sep; 103(36):1249-52. PubMed ID: 4584090
    [No Abstract]   [Full Text] [Related]  

  • 26. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
    Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
    Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tumor antigens recognized by T-lymphocytes in human cancers. New advances and therapeutic perspectives].
    Gaugler B; Olive D
    Pathol Biol (Paris); 1998 Dec; 46(10):771-8. PubMed ID: 9922993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concomitant immunization by the fully antigenic counterparts prevents modulated tumor cells from escaping cellular immune elimination.
    De Boer RJ; Michelson S; Hogeweg P
    J Immunol; 1986 Jun; 136(11):4319-27. PubMed ID: 2939142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy.
    Singh R; Paterson Y
    Expert Rev Vaccines; 2006 Aug; 5(4):541-52. PubMed ID: 16989634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Oncoimmunology: some fundamental problems of cancer immunotherapy].
    Nedospasov SA; Kuprash DV
    Mol Biol (Mosk); 2007; 41(2):355-68. PubMed ID: 17514902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dendritic cells and their applications in cancer immunotherapy--achievements and future prospects].
    Rossowska J; Pajtasz-Piasecka E
    Postepy Hig Med Dosw; 2003; 57(5):501-18. PubMed ID: 14737967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Capitalizing on the immunogenicity of dying tumor cells.
    Fonseca C; Dranoff G
    Clin Cancer Res; 2008 Mar; 14(6):1603-8. PubMed ID: 18347160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses.
    de Souza AP; Bonorino C
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1317-32. PubMed ID: 19761435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
    Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
    Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
    Zöller M; Matzku S
    Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?
    Quesnel B
    Expert Rev Vaccines; 2006 Dec; 5(6):773-81. PubMed ID: 17184216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mini-review: overcoming tumor-intrinsic resistance to immune effector function.
    Ganss R; Arnold B; Hämmerling GJ
    Eur J Immunol; 2004 Oct; 34(10):2635-41. PubMed ID: 15368278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.